These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 20213205)
21. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Debelak K; Morrone WR; O'Grady KE; Jones HE Am J Addict; 2013; 22(3):252-4. PubMed ID: 23617867 [TBL] [Abstract][Full Text] [Related]
22. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder. Becker WC; Ganoczy D; Fiellin DA; Bohnert AS J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475 [TBL] [Abstract][Full Text] [Related]
24. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence. Saleh MI Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188 [TBL] [Abstract][Full Text] [Related]
25. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. Rapeli P; Fabritius C; Alho H; Salaspuro M; Wahlbeck K; Kalska H BMC Clin Pharmacol; 2007 Jun; 7():5. PubMed ID: 17565668 [TBL] [Abstract][Full Text] [Related]
26. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Caldiero RM; Parran TV; Adelman CL; Piche B Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087 [TBL] [Abstract][Full Text] [Related]
27. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Lintzeris N; Leung SY; Dunlop AJ; Larance B; White N; Rivas GR; Holland RM; Degenhardt L; Muhleisen P; Hurley M; Ali R Drug Alcohol Depend; 2013 Jul; 131(1-2):119-26. PubMed ID: 23317685 [TBL] [Abstract][Full Text] [Related]
29. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526 [TBL] [Abstract][Full Text] [Related]
30. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Bell J; Byron G; Gibson A; Morris A Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011 [TBL] [Abstract][Full Text] [Related]
31. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. DiPaula BA; Menachery E J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264 [TBL] [Abstract][Full Text] [Related]
32. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Sullivan LE; Moore BA; Chawarski MC; Pantalon MV; Barry D; O'Connor PG; Schottenfeld RS; Fiellin DA J Subst Abuse Treat; 2008 Jul; 35(1):87-92. PubMed ID: 17933486 [TBL] [Abstract][Full Text] [Related]
33. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment. Savant JD; Barry DT; Cutter CJ; Joy MT; Dinh A; Schottenfeld RS; Fiellin DA Drug Alcohol Depend; 2013 Jan; 127(1-3):243-7. PubMed ID: 22771144 [TBL] [Abstract][Full Text] [Related]
34. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. Curcio F; Franco T; Topa M; Baldassarre C; Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796 [TBL] [Abstract][Full Text] [Related]
36. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence. Accurso AJ; Rastegar DA J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639 [TBL] [Abstract][Full Text] [Related]
37. Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone. Soeffing JM; Rastegar DA J Subst Abuse Treat; 2007 Dec; 33(4):401-4. PubMed ID: 17400414 [TBL] [Abstract][Full Text] [Related]
38. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Fiellin DA; Barry DT; Sullivan LE; Cutter CJ; Moore BA; O'Connor PG; Schottenfeld RS Am J Med; 2013 Jan; 126(1):74.e11-7. PubMed ID: 23260506 [TBL] [Abstract][Full Text] [Related]
39. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Rosenblatt RA; Andrilla CH; Catlin M; Larson EH Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888 [TBL] [Abstract][Full Text] [Related]